1 Medical Marijuana Stock: Your Ticket to a Billion-Dollar Market
- Cannabis-based therapies could put an end to the growing opioid epidemic.
- One undervalued pharmaceutical company is your entry point into the $11.9 billion medical marijuana market.
- Real Wealth Strategist readers get exclusive insight into this massive trend.
This couple — we’ll call them Rachel and Tom — have been family friends for as long as I can remember.
Hardly a weekend went by that we weren’t all out fishing or swimming off the coast of South Florida.
It was clear they weren’t ones to settle down. In fact, my pseudo aunt and uncle planned to spend their retirement years island-hopping.
They even bought a trawler to travel the world in.
But one day, Rachel collapsed on the deck of their boat. As time passed, she began to lose control over her body.
Her doctor diagnosed Rachel with a rare form of primary lateral sclerosis. It’s a disease that attacks your brain and nervous system.
She once described the constant discomfort as moving through thick mud. No matter how hard she tried, her body just couldn’t respond to her mind.
To make matters worse, there aren’t any treatments for Rachel’s disease.
The best her doctor could do was try to make her comfortable. So, he gave Rachel opioids. They ultimately drained her energy and took her ability to communicate.
Rachel had resigned herself to her condition. That is, until her daughter made a radical suggestion…
1 Controversial Drug Gave Rachel Her Life Back
Rachel’s daughter heard marijuana helped other people with the same issues. She suggested it as a new treatment.
Mind you, this was before the plant was legal in Florida.
The effects were almost instantaneous. Rachel found relief from her symptoms. She was able to enjoy the company of her family and friends again.
Better still, she no longer dealt with the drowsiness and mood swings she got from taking opioids.
It’s been seven years since her diagnosis. Rachel’s attitude remains positive even though her symptoms persist.
But not everyone in Rachel’s position can make the same claim.
You see, cannabis can help people with different diseases. It can treat forms of epilepsy, ease pain and even help prevent nausea and appetite loss.
But cannabis’s legal status stunts research because pot is still listed as a Schedule 1 drug. That category lists it as not having medical or health benefits.
As a result, most pharmaceutical companies weren’t willing to risk millions of dollars on research.
The Food and Drug Administration and the Drug Enforcement Administration could decline any development for a cannabis medication.
But all of that changed back in 2018.
Watch my video below to catch my latest marijuana market update.
Cannabis Makes Its Big Pharma Debut
In June of last year, GW Pharmaceuticals got the first cannabis-based drug approved in the U.S.
The drug, named Epidiolex, can treat two different forms of childhood epilepsy.
Epidiolex’s approval was a huge win for the pharmaceutical industry.
It encouraged other drug companies to start their own cannabinoid research and study pot’s health benefits compared to traditional medications.
This is good news for us as investors. It gives us the opportunity to get into an untapped market right as it’s about to take off…
A $100 Billion Market in the Making
One of marijuana’s biggest selling points is that it’s a nonaddictive pain treatment.
Pharmaceutical companies are still in the beginning stages of studying cannabis. The plant has hundreds of chemical compounds that can interact with our bodies.
But early research suggests that marijuana may be the solution to our growing opioid epidemic.
The National Institute on Drug Abuse shows that more than 1.7 million people in the U.S. suffer from substance abuse directly related to opioid pain relievers.
I’m not saying cannabis is a cure-all for each of those cases. But cannabinoid therapeutics could be a safer alternative for many chronic pain sufferers — just like it was for Rachel.
Pain management isn’t the only benefit that cannabis has to offer.
As I mentioned earlier, studies show that marijuana is also helpful for people who have gastrointestinal issues, epilepsy and autism.
And that’s just the tip of the iceberg.
As studies discover more cannabis-based health benefits, the market will only grow.
In fact, while the medicinal marijuana market hit $11.9 billion in 2018 … it will reach an enormous $100 billion by 2025.
That represents a compound annual growth rate of roughly 35%. That’s exactly the kind of momentum that we want to buy into.
But … a word of caution.
Many pharmaceutical companies are now scrambling to get in on this market — and not every one of them will be successful.
It’s important to find the real pioneers of the medical marijuana industry. Otherwise, you could end up losing your shirt making risky investments.
That’s where Real Wealth Strategist comes into play…
Buy the No. 1 Medical Marijuana Stock
In Real Wealth Strategist, my colleague Matt Badiali and I specialize in finding the best pot stocks the market has to offer.
Just this week, we homed in on a pharmaceutical company that’s changing the face of the medical marijuana market.
Even better, this stock’s share price is dragging lower because of the recent sell-off in the cannabis sector.
But our research shows that Wall Street is completely underestimating this stock’s current valuation. It should start to climb again soon.
In fact, sales in the fourth quarter are already taking off. It’s only a matter of time before this stock goes beyond our recommended buy-up-to price.
We’ve compiled the details of this company in a special report that you can check out here. I encourage you to read it now … while the company’s still trading for an incredible bargain.
Internal Analyst, Banyan Hill Publishing
P.S. Don’t forget to check out my YouTube channel ! Hit the subscribe button to receive a notification whenever I post new content.